Patients 'shunning' swine flu jab

12 April 2012

More than half of patients are turning down the swine flu vaccine, a snapshot survey has suggested.

A Pulse magazine poll of 107 GPs found some people were concerned about possible side-effects of the jab while others believed there was no need to have it because the virus is mild.

Family doctors are currently vaccinating people at high risk from swine flu, including pregnant women, health workers and those with asthma, heart disease and diabetes.

The poll of GPs in England found resistance to the jab was particularly high among pregnant women and, overall, only 46% of patients offered the vaccine are thought to have said yes.

One family doctor estimated that as few as one in 20 pregnant women were opting to have the vaccine.

Last week, the Government published online information and leaflets aimed at persuading pregnant women to have the vaccine. The number of new swine flu infections is currently hovering around 64,000 a week in England.

Public concern over the vaccine's safety has become heightened in recent months. There are several reasons people seem to be refusing the jab, including a belief that swine flu is a mild illness and recovery is relatively quick. While this is true for the majority of people, those in at-risk groups have been found to experience more complications. Some pregnant women are also worried that the jab has not been tested on their group. However, no vaccine of any kind is routinely tested on pregnant women. The jab has been approved for use in pregnant women by European and UK regulators.

Two vaccines are currently in use: Pandemrix, manufactured by GlaxoSmithKline, and Celvapan, manufactured by Baxter. A large amount of evidence exists which shows that vaccines similar to Celvapan are safe.

However, the Pandemrix vaccine has been the subject of more intense debate because it contains an adjuvant. This is a chemical which heightens the immune response and there is less available evidence on the safety of adjuvants. The adjuvant in Pandemrix is called squalene, which is extracted from fish oil.

Both the vaccine and adjuvant have been carefully evaluated by European regulators and the Department of Health. The World Health Organisation (WHO) has also reviewed the safety of adjuvants and found no cause for concern. Clinical trial data is being collected and monitored all the time and doctors and patients are encouraged to report any side-effects.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in